SEC Form 4 · accession 0001209191-17-048413
ACURA PHARMACEUTICALS, INC · ACUR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Emigh
Officer — VP Corporate Development
Period of report
Aug 9, 2017
Accepted (ET)
Aug 10, 2017 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000786947
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF3,F1,F2 | $0.45 | Aug 9, 2017 | A | 14,000 | A | Aug 9, 2018 | Aug 8, 2022 | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F1Exercise price is closing price of Issuer's common stock on August 9, 2017
- F2Option vesting and exercisability is accelerated upon a qualifying change of control.
- F3Not Applicable.